Spotlight on Hidradenitis Suppurativa: A Review of New 4-year Data on Secukinumab in HS, Plus More With Dr. Martina Porter

November 7, 2025

Apply Now: Incyte Launches the Incyte Ingenuity Awards in HS

November 3, 2025

Bimekizumab Produces Sustained Reductions in Pain and Draining Tunnels in HS Patients

October 31, 2025

Biosimilar News: U.S. FDA Expands Yuflyma’s Label to Include HS in Adolescents and UV in Kids

October 17, 2025

Phase 3 Data: Sonelokimab May Be Effective for HS; One Trial Shows High Placebo Rate

September 29, 2025

The Dermatology Digest Adds Four New Members to Its Editorial Advisory Board for 2026

September 25, 2025

EADV 2025 News: New Brivekimig Data Supports Targeting TNF and OX40L in HS

September 17, 2025

EADV 2025 Coverage: Incyte’s Povorcitinib Improves Moderate-to-severe HS at Week 24

September 17, 2025

HS Research Brief: Bimekizumab (Bimzelx, UCB) Provides Sustained Symptom Relief for up to 3 Years

September 17, 2025

Incyte Launches HS TRUTHS Campaign

September 3, 2025

Four Expert Strategies That Will Enhance HS Management

September 2, 2025

Key Takeaways From the Second Annual UCB HS Summit With Dr. Steve Daveluy

August 14, 2025